Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.6.1.2 (guanylate cyclase)
 8,497 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It has been reported that prostaglandin E2 (PGE2) had anti-inflammatory and analgesic effects, although it was well known that PGE2 combined with bradykinin (BK) showed proinflammatory and algesic effects. On the other hand, it has recently been known that BK showed an indirect activating effect on cathepsin B, a lysosomal enzyme, which may be mediated through calcium ion-dependent steps, followed by production of enkephalins (EK), endogenous anti-inflammatory and analgesic peptides, in the rat incisor pulp. The purpose of the present study is to examine whether PGE2 could have an effect on activation or release of cathepsin B in the pulp tissue, or not. Intact whole pulps of the rat incisors were incubated with N alpha-benzoyl-arginine-beta-naphthylamide (BANA), a substrate for cathepsin B, in the presence or absence of BK and PGE2 in Hanks solution (pH 7.4), in order to determine the BANA-degrading activity and EK producing activity. Both hydrocortisone and lidocaine which were stabilizers for lysosomal membrane markedly inhibited the BANA-degrading activities in the presence of BK, and in contrast, retinol, a labilizer for lysosomal membrane, significantly enhanced the BK-induced BANA-degrading activity. PGE2, like hydrocortisone and lidocaine, inhibited the BANA-degrading activity, in a dose-dependent manner, regardless of the presence or absence of BK, as well as resulted in a decrease of EK production in the pulp. Furthermore, both arginine, a cleavage product of BK by carboxypeptidase B, and arachidonic acid, which were endogenous activators for soluble guanylate cyclase, enhanced the BANA-degrading activity in the pulp homogenate.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Stabilizing effect of prostaglandin E2 on lysosomal membrane of the rat dental pulp]. 213 3

S-nitrosothiols may serve as carriers in the mechanism of action of endothelium-derived relaxing factor (EDRF) by stabilizing the labile nitric oxide (NO) radical from inactivation by reactive species in the physiological milieu and by delivering NO to the heme activator site of guanylyl cyclase. Low-molecular-weight thiols, such as cysteine and glutathione, form S-nitrosothiol adducts with vasodilatory and antiplatelet properties, and protein thiols can interact in the presence of NO and/or EDRF to form uniquely stable S-nitroso-proteins. We now show that the S-nitroso-proteins, S-nitroso-albumin, S-nitroso-tissue type plasminogen activator, and S-nitroso-cathepsin B, have potent antiplatelet effects with an IC50 of approximately 1.5 microM. In the dog, S-nitroso-albumin inhibits ex vivo platelet aggregation and significantly prolongs the template bleeding time from 2.15 +/- 0.13 (mean +/- SEM) to 9.70 +/- 1.24 minutes. The antiplatelet action of S-nitroso-proteins is associated with the stimulation of guanylyl cyclase and a significant decrease in fibrinogen binding to platelets. S-Nitroso-proteins undergo thiol-nitrosothiol exchange with low-molecular-weight thiols to form low-molecular-weight S-nitroso-thiols, and they also interact directly with the platelet surface, both of which processes facilitate generation of NO. These data suggest that S-nitroso-proteins are potent antiplatelet agents and may be intermediates in the antiplatelet mechanism of EDRF action.
 ...
PMID:Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. 838 13